[Outcome of acute lymphoblastic leukemia in the pediatric age group over a 29-year period (1972-2000)].
OBJECTIVE
To evaluate the progress achieved in the treatment of acute lymphoblastic leukemia (ALL) in our hospital.


METHODS
A total of 235 patients diagnosed with ALL in the central region of Cuba from 1972 to 2000 were included. Four groups were considered according to the diagnostic period and treatment protocol. Group 1 was composed of 20 patients who did not receive a uniform treatment regimen. The remaining groups were treated with different protocols of the Latin American Group for Malignant Hemopathy Therapy (Glathem). Group 2 was treated with less aggressive classical regimens from the 1970s, and groups 3 and 4 received more aggressive regimens, type Berlin-Frankfurt-Munster (BFM). Intravenous high-dose methotrexate was used in group 4 but not in group 3. Classification by prognostic groups was based on age and leukocyte count.


RESULTS
Of 215 patients included in the Glathem protocols, remission occurred in 197 (91.6%). Overall survival in the distinct treatment groups progressively increased during the study period, from a 5-year survival of 15% in group 1 to 72% in group 4. Event-free survival in patients included in the Glathem protocols increased from 42% in group 2 (classical protocols) to 68.7% in the BFM protocols (groups 3 and 4). Significant differences were found among the different treatment and prognostic groups considered.


CONCLUSIONS
During the period analyzed, survival in children with ALL progressively increased in parallel with improved treatment regimens. These results demonstrate the importance of well-programmed polychemotherapy to achieve prolonged survival and a high percentage of cure in this disease.
Hospital Pediátrico Universitario José Luis Miranda de Santa Clara, Villa Clara, Cuba. bvergara@capiro.vcl.sld.cu
B
B
Vergara Domínguez
T
T
Cedré Hernández
L
L
Martínez Cárdenas
C
C
López García
F
F
González Seivane
V
V
Pichs León
M
M
Alegret Martínez
S
S
Pérez García
G
G
Courell Martin
M E
ME
Castro Martínez
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality*; D016019:Survival Analysis